For decades, cancer immunotherapy has focused primarily on CD8 + cytotoxic T lymphocytes as the main executors of tumor cell killing. However, growing clinical and single-cell sequencing evidence ...

The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDAŃSK, Poland, ...

The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDANSK, Poland ...

Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited ...

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous melanomas by disease type.

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...

Vaccines play an increasingly vital role in protecting our health. They directly protect us against a growing number of diseases, but there is more: Evidence is accumulating that they also help keep ...

Results demonstrated early signals of C-peptide preservationT1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing ...